echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Junshi Biologics' JS110 (XPO1 inhibitor) clinical trial application was approved by the US FDA

    Junshi Biologics' JS110 (XPO1 inhibitor) clinical trial application was approved by the US FDA

    • Last Update: 2022-10-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Shanghai, August 25, 2022 /PRNewswire/ -- On August 25, 2022, Beijing time, Junshi Biologics announced that the clinical trial application of the XPO1 inhibitor WJ01024 tablets (project code: JS110) jointly developed by the company and Micro Bio has been approved by
    the US Food and Drug Administration (FDA).


    XPO1 is the primary protein that mediates nuclear output and plays a vital role
    in maintaining cellular homeostasis.


    JS110 is a small molecule inhibitor of the nucleo-exporting protein XPO1 that is clinically intended for the treatment of patients with
    advanced tumors.


    In April 2021, the clinical trial application for JS110 was approved by
    the State Drug Administration (NMPA).


    Concentrate:

    1.


    2.


    References:

    1.


    About Junshi Biology

    Founded in December 2012, Junshi Biologics is an innovation-driven biopharmaceutical company
    dedicated to the discovery, development and commercialization of innovative therapies.


    With the core platform technology of protein engineering, Junshi Bio is at the forefront of international macromolecular drug research and development, and has obtained the first domestic anti-PD-1 monoclonal antibody NMPA listing approval, domestic anti-PCSK9 monoclonal antibody NMPA clinical application approval, the world's first therapeutic tumor anti-BTLA blocking antibody in China NMPA and the US FDA clinical application approval, and is currently carrying out a number of Phase I/II clinical trials
    in China and the United States.


    Since the beginning of the outbreak of the epidemic in 2020, Junshi Bio has responded quickly, joined hands with domestic and foreign scientific research institutions and enterprises to fight the epidemic, used technology accumulation to quickly develop a number of innovative drugs for the treatment of COVID-19, and actively assumed the social responsibility
    of Chinese pharmaceutical enterprises 。 These include: Etersvimab (JS016), the first domestic antibody to enter the clinical stage and participate in the global anti-epidemic anti-COVID-19 neutralization antibody, was granted emergency use authorization in more than 15 countries and regions in 2021, and the new oral nucleoside anti-new coronavirus drug VV116 (JT001) has entered the international multi-center phase III registered clinical research stage, as well as other types of drugs, continuing to contribute to the global fight against the epidemic
    .


    At present, Junshi Bio has more than 3,100 employees around the world, distributed in San Francisco and Maryland, Shanghai, Suzhou, Beijing, Guangzhou and so on
    .


    Official WeChat: Junshi Bio

    Source: Junshi Bio

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.